Background: Romiplostim is a thrombopoietin-mimetic peptibody for adult refrac-
| INTRODUC TI ON
Primary immune thrombocytopenia (previously known as idiopathic thrombocytopenic purpura; ITP) is a rare disorder characterised by peripheral blood platelet count below 100 × 10 9 /L in the absence of any detectable underlying cause.
1,2 ITP, particularly when platelet counts are < 30 × 10 9 /L, is associated with an increased risk of bleeding which can be major and, at times, fatal; bleeding risk increases with increasing age. 3 The annual incidence of newly diagnosed ITP in adults is estimated to range from approximately 1.6 to 3.9 per 100 000 persons. [4] [5] [6] [7] [8] Persistence or chronicity of the disorder is common and was reported to develop in approximately 67% of incident primary adult ITP patients after a mean follow-up period of 18 months. 5 The one-year period prevalence of diagnosed ITP in adults (aged older than 16 or 18 years) is estimated to range from 4.6 to 12.1 per 100 000 persons. [9] [10] [11] Current first-line treatment for ITP includes corticosteroids and intravenous immunoglobulin (IVIg), while second-line and subsequent treatments include splenectomy, thrombopoietin receptor agonists (TPO-RAs), rituximab, immunosuppressants (azathioprine, cyclosporine and mycophenolate), cyclophosphamide, danazol and dapsone. 2, 12 Complications of treatment, such as thromboembolic and bleeding risks after splenectomy, and infections caused by immunodeficiency-inducing therapies (immunosuppressive drugs, splenectomy), contribute to mortality and morbidity. [13] [14] [15] TPO-RAs, romiplostim 16 and eltrombopag, 17 are approved for use in chronic ITP in adults in whom ITP is refractory to other treatments. As shown in randomised double-blind trials, [16] [17] [18] [19] [20] [21] [22] TPO-RAs stimulate megakaryopoiesis and increase platelet counts, resulting in fewer bleeding episodes and reduction in rescue medication use. Longterm responses in patients who are no longer receiving TPO-RAs (ie sustained remission) have been reported in the range of 10%-32% of patients in clinical trials 22 and observational studies. [23] [24] [25] Adverse events of interest for TPO-RAs include bone marrow reticulin fibrosis, thromboembolic events, neutralising antibodies (romiplostim only), increased liver enzymes and cataracts (eltrombopag only). [26] [27] [28] [29] [30] Romiplostim is a thrombopoietin-mimetic peptibody licensed in the EU for use in splenectomised and non-splenectomised patients with chronic ITP that is refractory to other treatments (eg corticosteroids, intravenous immunoglobulins). These were combined with the patients' data collected from hospital and general practice records to form the overall data set which was analysed for this study. The first recorded use of romiplostim was defined as the index date. The pre-index period was defined as a maximum of 6 months prior to the index date, except for comorbidities, which were included up to 12 months before index. For the present study, follow-up started at the first exposure to romiplostim (index date) and continued until withdrawal from the registry, death (utilising data from ONS), loss to follow-up or the end of the study period (31 January 2015), whichever was earlier.
| Study design

| Inclusion criteria
| Statistical analyses
To describe the cohort's characteristics, frequencies and percent- was generated for each estimate.
| RE SULTS
| Patients
Out of 1440 patients with primary ITP in the UK Adult ITP Registry, 118 adult patients were eligible for inclusion in this study. The baseline demographic and clinical characteristics of the study population are shown in Table 1 . The median age at diagnosis was 58.5 years (IQR 35.8, 73.1), and 39% of patients were aged 65 or older. Fortynine per cent of patients were women, and the majority (81%) were
Caucasian. The most common comorbidities were hypertension (36%), type 2 diabetes (18%) and other autoimmune disease (13%).
| Treatment of ITP prior to romiplostim initiation
ITP therapies received before the initiation of romiplostim are shown in Table 2 . Ninety-seven per cent of patients received at least one prior treatment, and 77% received more than three treatments before romiplostim. Twenty-two per cent of patients had previously undergone splenectomy. The most common ITP medications prior to romiplostim initiation were steroids (90%), IVIg (77%), rituximab (57%) and immunosuppressants (51%). Platelet transfusions were administered in 35% of patients.
| Romiplostim treatment
The median time from ITP diagnosis to romiplostim initiation was 3.3 years (IQR: 0.9, 8.1) ( Table 3) . Almost three-quarters of patients (73%) initiated romiplostim 1 year or more after ITP diagnosis, and 27% of patients initiated romiplostim within 1 year of ITP diagnosis (12% within 3 months, 6% between 3 and 6 months and 9% be- frequently administered ITP medications were steroids (32%), IVIg (27%), eltrombopag (25%) and immunosuppressants (20%) ( Table 4) .
We were not able to establish whether these medications were used as rescue medications or for routine standard of care later in the course of ITP care. Of the 29 patients who received eltrombopag after initiation of romiplostim, the median time from romiplostim initiation to eltrombopag use was 22.7 months (IQR: 7.6, 29.0), with a reduced time to initiation in non-splenectomised vs splenectomised patients (14.6 vs 28.4 months, respectively).
| Platelet count
The mean platelet count within 2 weeks before romiplostim initiation was 38 × 10 
| Bleeding
Ninety-two (78%) patients had at least one bleeding event at any site (seven events per patient-year during the up to 6-month period before the initiation of romiplostim 
| D ISCUSS I ON
This retrospective observational study in adults with primary ITP participating in the UKITP Registry was conducted to provide a better understanding of the treatment of primary ITP patients with Similarly, we caution that the design of the study precludes any conclusions on the effects of romiplostim on platelet concentrations and bleeding rates.
An important limitation of the study is the statistical precision of the estimates due to a small sample size compared to the total size of the registry. As the more severe and chronic cases of ITP are more likely to receive romiplostim based on the product labelling, the results may not be fully extrapolated to the overall primary ITP population, many of whom have milder disease phenotypes. Another limitation of the study is the lack of information on the severity of thrombocytopenia of ITP. Confounding for treatment remains the main challenge to the interpretation of this observational study due to changes during the course of the study in the romiplostim indication, allowing for second-line use as well as newly diagnosed patients having access earlier in their treatment pathway compared to prevalent patients in this study. An additional confounder is the evolution in physician experience in prescribing romiplostim that occurred during the course of the study.
In conclusion, the results of this study highlight the complexity of ITP treatment in routine practice, with a wide number of different types of ITP therapeutic treatments used within this UKITP cohort.
In particular, the study provides insight into the use of romiplostim in patients with primary ITP in routine practice within the UK. 
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